Fibroblast Growth Factor 23 in Multiple Myeloma Patients with Renal Impairment

被引：0
作者：
Ibrahim, Nahed Moawad [1 ]
El Afifi, Amal Mostafa [1 ]
Abdelallim, Nada Shawky Rizk [1 ]
Abdullah, Nour El Hoda Hussein [1 ]
机构：
[1] Ain Shams Univ, Clin Hematol & Bone Marrow Transplantat Unit, Fac Med, Cairo, Egypt
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
MM; fibroblast growth factor 23; newly diagnosed multiple myeloma; renal impairment;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-299
引用
收藏
页码：S434 / S434
页数：1
相关论文
共 50 条
  • [21] 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment
    Jung, Sung-Hoon
    Moon, Joon Ho
    Back, Dong Won
    Ahn, Seo-Yeon
    Yang, Deok-Hwan
    Ahn, Jae-Sook
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) : E189 - E190
  • [22] Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantation
    Mohyuddin, Ghulam Rehman
    Abbasi, Saqib
    Okoniewski, Maire
    McClune, Brian
    Abdallah, Al-Ola
    Ganguly, Siddhartha
    McGuirk, Joseph
    Shune, Leyla
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 105 (05) : 571 - 577
  • [23] A Systematic Review on the Use of Bortezomib in Multiple Myeloma Patients with Renal Impairment: What Is the Published Evidence?
    Piro, Eugenio
    Molica, Stefano
    ACTA HAEMATOLOGICA, 2011, 126 (03) : 163 - 168
  • [24] Prognosis of concurrent renal impairment at diagnosis of multiple myeloma: a systematic review
    Zhang, Yanjie
    Pan, Juan
    Kang, Haixin
    Peng, Shuotao
    Tung, Tao-Hsin
    Shen, Bo
    ANNALS OF MEDICINE, 2024, 56 (01)
  • [25] Renal impairment at presentation in multiple myeloma continues to be associated with poor survival
    Laing, Alison A.
    Geddes, Colin
    Soutar, Richard
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (06) : 901 - 902
  • [26] Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States
    Qian, Yi
    Bhowmik, Debajyoti
    Bond, Christopher
    Wang, Steven
    Colman, Sam
    Hernandez, Rohini K.
    Cheng, Paul
    Intorcia, Michele
    CANCER MEDICINE, 2017, 6 (07): : 1523 - 1530
  • [27] Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment
    Yang, Guangzhong
    Chen, Wenming
    Wu, Yin
    CHINESE JOURNAL OF CANCER RESEARCH, 2013, 25 (02) : 155 - 160
  • [28] The Impact of Renal Impairment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation With Melphalan Conditioning
    Ursu, Sorana G.
    Maples, Samantha
    Williams, Kiersten J.
    Patrus, Gina
    Samhouri, Yazan
    Fazal, Salman
    Mewawalla, Prerna
    Sadashiv, Santhosh
    JOURNAL OF HEMATOLOGY, 2023, 12 (05) : 201 - 207
  • [29] Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment
    Guangzhong Yang
    Wenming Chen
    Yin Wu
    Chinese Journal of Cancer Research, 2013, 25 (02) : 155 - 160
  • [30] Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA
    Morabito, Fortunato
    Gentile, Massimo
    Ciolli, Stefania
    Petrucci, Maria T.
    Galimberti, Sara
    Mele, Giuseppe
    Casulli, Antonio F.
    Mannina, Donato
    Piro, Eugenio
    Pinotti, Graziella
    Palmieri, Salvatore
    Catalano, Lucio
    Callea, Vincenzo
    Offidani, Massimo
    Musto, Pellegrino
    Bringhen, Sara
    Baldini, Luca
    Tosi, Patrizia
    Di Raimondo, Francesco
    Boccadoro, Mario
    Palumbo, Antonio
    Cavo, Michele
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 84 (03) : 223 - 228
12345